Skip to content
The People's CodeSearch
Menu

Changes to the Code

H.R. 8339 · Drug Origin Transparency Act of 2026 ·

In committee · step 2 of 5

Sections are cited like “7 U.S.C. § 2012”: 7 of the , 2012.

21 U.S.C. § 360 Registration of producers of drugs or devices

+13 −1Shown
More for 21 U.S.C. § 360
Read § 360Only this section
2 changes the bill asks for here, 2 carried out
  1. Carried out:

    in subparagraph (A), by adding or (2) after paragraph (1); and

  2. Carried out:

    by adding at the end the following:(C) Each report submitted pursuant to subparagraph (A) with respect to a drug shall— (i) include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as— (I) the identity of the respective suppliers …

§ 360(j)Filing of lists of drugs and devices manufactured, prepared, propagated and compounded by registrants; statements; accompanying disclosures(2)–(5)

Start of § 360 to (j)(2)(C) unchanged

WhereMarkThe Code nowMarkAs the bill would leave it
(2)(D)(D) (D)
Any material change in any information previously submitted pursuant to this paragraph or paragraph (1).Any material change in any information previously submitted pursuant to this paragraph or paragraph (1).
(3)(3) (3)
(3)(A)(A) (A)
Each person who registers with the Secretary under this section with regard to a drug shall report annually to the Secretary on the amount of each drug listed under paragraph (1) that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution. Such information may be required to be submitted in an electronic format as determined by the Secretary. The Secretary may require that information required to be reported under this paragraph be submitted at the time a public health emergency is declared by the Secretary under section 247d of title 42.Each person who registers with the Secretary under this section with regard to a drug shall report annually to the Secretary on the amount of each drug listed under paragraph (1) [inserted: or (2) ]that was manufactured, prepared, propagated, compounded, or processed by such person for commercial distribution. Such information may be required to be submitted in an electronic format as determined by the Secretary. The Secretary may require that information required to be reported under this paragraph be submitted at the time a public health emergency is declared by the Secretary under section 247d of title 42.
(3)(B)(B) (B)
By order of the Secretary, certain biological products or categories of biological products regulated under section 262 of title 42 may be exempt from some or all of the reporting requirements under subparagraph (A), if the Secretary determines that applying such reporting requirements to such biological products or categories of biological products is not necessary to protect the public health.By order of the Secretary, certain biological products or categories of biological products regulated under section 262 of title 42 may be exempt from some or all of the reporting requirements under subparagraph (A), if the Secretary determines that applying such reporting requirements to such biological products or categories of biological products is not necessary to protect the public health.
(3)(C)(C) [inserted: ]
[inserted: Each report submitted pursuant to subparagraph (A) with respect to a drug shall—]
(3)(C)(i)(i) [inserted: ]
[inserted: include additional information as may be specified by the Secretary in regulation or guidance regarding the supply chain for such drug, such as—]
(3)(C)(i)(I)(I) [inserted: ]
[inserted: the identity of the respective suppliers of each active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material used in such manufacture, preparation, propagation, compounding, or processing of the drug; and]
(3)(C)(i)(II)(II) [inserted: ]
[inserted: the respective amounts of such drug that were manufactured, prepared, propagated, compounded, or processed using an active pharmaceutical ingredient, active pharmaceutical ingredient intermediate, and in-process material from each such identified supplier; and]
(3)(C)(ii)(ii) [inserted: ]
[inserted: be submitted more frequently than annually, in accordance with a reporting schedule as may be specified by the Secretary in such regulation or guidance, but not more frequently than 4 times per year.]
(3)(D)(D) [inserted: ]
[inserted: Any additional information specified in regulation or guidance pursuant to subparagraph (C) shall be a required element of reports under this paragraph not earlier than 6 months after the date on which such regulation or guidance is issued in final form (and in no event shall the absence of any regulation or guidance issued under subparagraph (C) affect the requirement to report as described in subparagraph (A)).]
(4)(4) (4)
The Secretary may also require each registrant under this section to submit a list of each drug product which (A) the registrant is manufacturing, preparing, propagating, compounding, or processing for commercial distribution, and (B) contains a particular ingredient. The Secretary may not require the submission of such a list unless he has made a finding that the submission of such a list is necessary to carry out the purposes of this chapter.The Secretary may also require each registrant under this section to submit a list of each drug product which (A) the registrant is manufacturing, preparing, propagating, compounding, or processing for commercial distribution, and (B) contains a particular ingredient. The Secretary may not require the submission of such a list unless he has made a finding that the submission of such a list is necessary to carry out the purposes of this chapter.
(5)(5) (5)
The Secretary shall require persons subject to this subsection to use, for purposes of this subsection, the unique facility identifier systems specified under subsections (b)(3) and (i)(4) with respect to drugs. Such requirement shall not apply until the date that the identifier system under subsection (b)(3) or (i)(4), as applicable, is specified by the Secretary.The Secretary shall require persons subject to this subsection to use, for purposes of this subsection, the unique facility identifier systems specified under subsections (b)(3) and (i)(4) with respect to drugs. Such requirement shall not apply until the date that the identifier system under subsection (b)(3) or (i)(4), as applicable, is specified by the Secretary.

Rest of § 360 unchanged

21 U.S.C. § 352 Misbranded drugs and devices

Couldn't place 6 changes
More for 21 U.S.C. § 352
Read § 352Only this section

The bill's words for this section

  1. Not carried out:

    by striking (b) If in a package and inserting (b)(1) If in a package;

    The bill points to paragraph (b) of § 352, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (b) in /us/usc/t21/s352
  2. Not carried out:

    by striking a label containing (1) the name and place and inserting(A) the name and place a label containing—;

    The bill points to paragraph (b) of § 352, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (b) in /us/usc/t21/s352
  3. Not carried out:

    by striking or distributor; and (2) an accurate statement and inserting(B) an accurate statement or distributor; and;

    The bill points to paragraph (b) of § 352, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (b) in /us/usc/t21/s352
  4. Not carried out:

    by striking under clause (2) of this paragraph and inserting under this clause; and

    The bill points to paragraph (b) of § 352, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (b) in /us/usc/t21/s352
  5. Not carried out:

    by inserting at the end the following:(2) (A) Subject to clause (C), if it is a drug, including an active pharmaceutical ingredient, unless it bears a label containing the name and place of business, and unique facility identifier of the original manufacturer of such drug or active pharmaceutical ingredient, except …

    The bill points to paragraph (b) of § 352, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailtarget not found: no paragraph (b) in /us/usc/t21/s352
  6. Not carried out:

    by inserting after paragraph (c) the following:(d) (1) Subject to subparagraph (2), if it is a drug, including an active pharmaceutical ingredient, unless it bears labeling containing the name and place of business of— (A) the original manufacturer of each active pharmaceutical ingredient; (B) each manufacturer, if different …

    The bill points to paragraph (c) of § 352, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.

    Technical detailno paragraph (c) in /us/usc/t21/s352

Step through the changes